Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
343
¥ millions (year-on-year improvement in loss before income taxes and net loss)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationFY2026/08 Second Quarter (Interim Period)5 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit¥-662 million
Net income¥-633 million
Selling, general and administrative expenses¥152 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Decrease in rogocekib active pharmaceutical ingredient and formulation-related costs¥329 million
- Decrease in patent-related costs included in other selling, general and administrative expenses
New initiatives
- Start of an expanded cohort in the U.S. Phase 1/2 trial of rogocekib
- Two joint research projects in ophthalmic diseases with Senju Pharmaceutical Co., Ltd. and D. Western Therapeutics Institute, Inc.
- Joint research on CTX-439 with Kyoto University
- Re-out-licensing of CTX-177 and partnership discussions for multiple pipelines
Key KPIsA metric the company considers important as a management benchmark.
- Total rogocekib cases enrolled in Japan and the United States102 people
- Rogocekib cases enrolled in Japan60 Engagements
- Rogocekib cases enrolled in the United States42 Engagements
Market Size / Share
- RegionJapanNew AML casesApproximately 9,000 patientsPrescription drug salesApproximately $72 billion
- RegionUnited StatesNew AML casesApproximately 22,000 patientsPrescription drug salesApproximately $730 billion
- RegionEuropeNew AML casesApproximately 13,500 peoplePrescription drug salesApproximately $360 billion
Number of employees
Number of Employees23 people
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | FY2026/08 Second Quarter (Interim Period) |
| Operating profit | ¥-662 million |
| Net income | ¥-633 million |
| Selling, general and administrative expenses | ¥152 million |
| Breakdown of Factors Affecting the Change | Factors Decrease in rogocekib active pharmaceutical ingredient and formulation-related costs / Amount ¥329 million, Factors Decrease in patent-related costs included in other selling, general and administrative expenses / Amount Not disclosed |
| Key KPIs | Indicator name Total rogocekib cases enrolled in Japan and the United States / Value 102 people / Year on year against the same period last year Not disclosed, Indicator name Rogocekib cases enrolled in Japan / Value 60 Engagements / Year on year against the same period last year Not disclosed, Indicator name Rogocekib cases enrolled in the United States / Value 42 Engagements / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 23 people / Change during the period Not disclosed / Hiring plan Not disclosed |
| Market Size / Share | Region Japan / New AML cases Approximately 9,000 patients / Prescription drug sales Approximately $72 billion, Region United States / New AML cases Approximately 22,000 patients / Prescription drug sales Approximately $730 billion, Region Europe / New AML cases Approximately 13,500 people / Prescription drug sales Approximately $360 billion |
| New initiatives | Start of an expanded cohort in the U.S. Phase 1/2 trial of rogocekib, Two joint research projects in ophthalmic diseases with Senju Pharmaceutical Co., Ltd. and D. Western Therapeutics Institute, Inc., Joint research on CTX-439 with Kyoto University, Re-out-licensing of CTX-177 and partnership discussions for multiple pipelines |
Items this document does not state (21)
Net SalesOrdinary incomeGross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Rogocekib research and development expenses decreased due to a ¥329 million reduction in active pharmaceutical ingredient and formulation-related costs, while other selling, general and administrative expenses decreased due to lower patent-related costs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.